Brian Windsor
Net worth: 30 021 $ as of 2026-05-30
Net worth: 30 021 $ as of 2026-05-30
Brian J.
Windsor was the founder of Texagen, Inc., founded in 1999, where the title held was Vice President-Research & Development from 1999 to 2003.
The current job is President, Chief Executive Officer & Director at Rein Therapeutics, Inc. starting in 2024.
Former jobs include President, Chief Executive Officer & Director at Lung Therapeutics LLC; Director & Chief Scientific Officer at TFF Pharmaceuticals, Inc. from 2018 to 2022; Senior Vice President-Portfolio Company Management at Emergent Technologies, Inc. from 2010 to 2013; President at Reveal Sciences LLC; President at Mimetic Solutions LLC; Chief Technology Officer at Auxano Biomedical LLC; President at Coradyn Biosystems LLC; President at Enavail LLC from 2009 to 2013; and President at Appian Labs LLC.
Education includes undergraduate and doctorate degrees from The University of Texas at Austin, with the doctorate conferred in 2000.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-07 | 27,046 ( 0.03% ) | 30 021 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| REIN THERAPEUTICS INC. | Chief Executive Officer | 2024-03-10 |
| Companies | Position | End |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2022-03-20 |
Emergent Technologies, Inc.
Emergent Technologies, Inc. Investment ManagersFinance Emergent Technologies invests in companies located in the United States. The firm focuses on life sciences and technology sectors and industries. It provides financing for early stage capital requirements. | Corporate Officer/Principal | 2013-02-28 |
Enavail LLC
Enavail LLC Pharmaceuticals: OtherHealth Technology Produces bioactive peptides and compounds for clinical research | President | 2013-02-28 |
Texagen, Inc. | Founder | 2003-06-30 |
Lung Therapeutics LLC
Lung Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel pipeline of first-in-class medicines for fibrosis | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 12 |
|---|---|
Rein Therapeutics, Inc.
Rein Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops stapled peptide drugs | Health Technology |
Lung Therapeutics LLC
Lung Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel pipeline of first-in-class medicines for fibrosis | Health Technology |
The University of Texas at Austin
The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Emergent Technologies, Inc.
Emergent Technologies, Inc. Investment ManagersFinance Emergent Technologies invests in companies located in the United States. The firm focuses on life sciences and technology sectors and industries. It provides financing for early stage capital requirements. | Finance |
Reveal Sciences LLC
Reveal Sciences LLC Specialty StoresRetail Trade Provides personal care products | Retail Trade |
Mimetic Solutions LLC
Mimetic Solutions LLC Pharmaceuticals: MajorHealth Technology Develops and distributes drugs & chemicals | Health Technology |
Auxano Biomedical LLC
Auxano Biomedical LLC Medical SpecialtiesHealth Technology Designs and distributes medical devices | Health Technology |
Coradyn Biosystems LLC
Coradyn Biosystems LLC SemiconductorsElectronic Technology Develops technology for sensor applications | Electronic Technology |
Texagen, Inc. | |
Enavail LLC
Enavail LLC Pharmaceuticals: OtherHealth Technology Produces bioactive peptides and compounds for clinical research | Health Technology |
Appian Labs LLC
Appian Labs LLC Pharmaceuticals: MajorHealth Technology Provides drug design and delivery services | Health Technology |
TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
Select your edition
All financial news and data tailored to specific country editions